Insulin-like Growth Factor Binding Protein-5 human
SIGMA/I8529 - >90% (SDS-PAGE), recombinant, expressed in NSO cells, lyophilized powder
Synonym: IGFBP-5
MDL Number: MFCD03457235
Product Type: Chemical
| assay | >90% (SDS-PAGE) |
| biological source | human |
| form | lyophilized powder |
| impurities | endotoxin, tested |
| mol wt | 34 kDa by SDS-PAGE (reducing) |
| calculated mol wt ~28 kDa | |
| packaging | pkg of 25 μg |
| potency | 0.5-1.5 mg per mL ED50 |
| Quality Level | 100 ![]() |
| recombinant | expressed in NSO cells |
| storage temp. | −20°C |
| UniProt accession no. | P24593 ![]() |
| Analysis Note: | The biological activity is measured by its ability to inhibit recombinant human IGF-1 or IGF-II on MCF-7 cells. |
| Biochem/physiol Actions: | Binds to bone cells and is the predominant insulin-like growth factor binding protein in bone; when binding the extracellular matrix, it modulates IGF activity. |
| Biochem/physiol Actions: | IGFBP-5 (insulin-like growth factor binding protein-5) interacts with IGFs and thereby controls IGF activity. High levels of IGFBP5 are present in systemic sclerosis and idiopathic pulmonary fibrosis conditions. It also plays a crucial role in cancer progression. |
| Biochem/physiol Actions: | IGFBP-5 binds to bone cells and is the predominant insulin-like growth factor binding protein in bone. When IGFBP-5 binds the extracellular matrix, it modulates IGF activity. Mouse, human, and rat IGFBP-5 share 97% homology. |
| General description: | The gene IGFBP-5 (insulin-like growth factor binding protein-5) is mapped to human chromosome 2q35. |
| Packaging: | 25 μg in glass insert |
| Physical form: | Lyophilized from a 0.2 μm filtered solution in 30% acetonitrile and 0.1% TFA. |
| RIDADR | NONH for all modes of transport |
| WGK Germany | WGK 3 |
| Flash Point(F) | Not applicable |
| Flash Point(C) | Not applicable |
| Purity | >90% (SDS-PAGE) |
| Storage Temp. | −20°C |
| UNSPSC | 51111800 |

